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An unexpected route for the synthesis of N,N-dialkyl formamidines has been reported by the reaction of
amines with N,N-dialkyl formamides and phenyl chloroformate.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Formamidines are the key intermediates for the construction of
heterocycles1 and functional group transformations.2 They have
also been employed as pharmacological agents,3 protecting groups
for primary amines,4 and as a support linker in solid phase syn-
thesis.5 The use of formamidines as chiral auxiliaries in asymmetric
synthesis6 and as ligand for metal-catalyzed hydrosilylation and
epoxidation has also been reported.7 The methods for the synthesis
of formamidines can largely be divided into three categories. The
ﬁrst involves the use of N,N-dialkyl formamide dialkylacetals with
or without a catalytic amount of acid. The second involves coupling
agents, such as POCl3, P2O5, PCl5, (COCl)2, SOCl2, acid chlorides,
sulfonylchlorides, PyBOP, and triﬂuoroacetic anhydride.8 The last
involves the use of isolated iminium salt like vilsmeier reagent,
which is related to the method of this report.9 Recently, a new
approach using NaI and TBHP to make N-sulfonyl formamidine has
been reported.10 As a part of our medicinal chemistry research
program we required carbamate 3, for which we attempted the
reaction of phenyl chloroformate with amine 1 (Scheme 1). It was
expected that the nucleophilic substitution would lead to the car-
bamate. However the product obtained was conﬁrmed as for-
mamidine 2, strongly suggesting the formation of a reactivemail address: ydgong@dong-
r Ltd. Open access under CC BY-NC-NDintermediate between N,N-dimethylformamide and phenyl chlor-
oformate, which was reacting with amines (Scheme 2). These
ﬁndings have not been reported, and have encouraged us to in-
vestigate the formamidine synthesis.
2. Results and discussion
We initially selected 3-aminopyridine and aminopyrazine to
study the optimal conditions. The reaction proceeded well, but
extraction with EtOAc was difﬁcult due to its good solubility in
water. To solve the problem, we used 6-chloro-2-aminopyrazine as
a model substrate since it is well extracted with EtOAc. After
selecting a model compound, we investigated the necessity of
K2CO3 in the methodology and found that K2CO3 was not necessary
for the reaction (Table 1, entries 1e4). Instead, the reaction required
more phenyl chloroformate for completion. In the absence of the
base, the product can be obtained as HCl salt via simple ﬁltration,
which makes the puriﬁcation much easier. Two other chlor-
oformates were also screened to compare their reactivity. Among
the chloroformates (Table 1, entries 4 and 5), p-nitrophenyl chlor-
oformate was found to show similar results to that of phenylScheme 1.
 license.
Table 2
Scope of the methoda
Entry Product Time [min] Yieldb [%]
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ering the price of the two aryl chloroformates, phenyl chlor-
oformate was found to be the reagent of choice for the reaction.Table 1
Reaction condition screeninga
Entry Base [equiv.] R [equiv] Time [min] Yieldb [%]
1 K2CO3 (2.7) Ph (2.0) 5 79
2 K2CO3 (3.0) Ph (2.2) 5 85
3 d Ph (2.0) 5 86c
4d d Ph (2.0) 5 84c
5 d Et (2.0) 5 12
6e d p-NitroPh (2.0) 5 84
a Reaction conditions: DMF (1 ml) and chloroformate were stirred for 5 min with
base or not before addition of the 6-chloro-2-aminopyraizne (1 mmol).
b Isolated yield.
c Obtained as HCl salt.
d DMF (0.5 ml).
e DMF (2 ml).
Scheme 2.
1c 6b 5 81
2c 6c 5 87
3d 6d 20 71
4e 6e 20 d
5 6f 5 87
6 6g 5 95
7 6h 5 79
8 6i 5 70
9 6j 5 90
10 6k 5 59
11 6l 10 60
12 6m 10 86
13 6n 5 50
14 6o 5 40
15 6p 10 59
a Reaction conditions: DMF (1 ml) and phenyl chloroformate (2 equiv) were
stirred for 5 min at rt before addition of the amines (1 mmol).
b Isolated yield.
c Phenyl chloroformate (1.5 equiv) was used.
d 4.5 equiv of phenyl chloroformate.
e 7 equiv of phenyl chloroformate.To study the reaction details, DMF and phenyl chloroformate
were mixed (1:1 molar ratio) and stirred for 5 min, and diluted into
CDCl3. The 1H NMR spectrum indicated the existence of iminium
salt, and that the DMF was completely consumed. However we
were unable to conﬁrm the intermediacy of either 4 or 5 because
bubbles, suspected as CO2 were observed in the mixture while
stirring. A literature survey revealed the isolation of an iminium salt
4, which is used as a chlorinating agent.11 We also can isolate the
intermediate 4 from the described procedure. It was thus con-
cluded that the intermediate 5 formed initially underwent de-
carboxylation to form the intermediate 4. The isolation of the
intermediate 4 answers the formation of the formamidines
(Scheme 2).
We started to explore the scope and limitations of the method
(Table 2). It was found that a greater equivalent of the phenyl
chloroformate has to be used as the nucleophilicity of amines de-
creases (Table 2, entries 1e4). In the case of trihaloaminopyrazine
(Table 2, entry 4), the reaction worked well but the product could
not be obtained due to its instability, both in the protic solvent and
in the air. It easily turned back to the amine. Nitro, methoxy,hydroxy, methyl ester, carboxylic acid, and acetyl-substituted aryls
also gave the desired products (Table 2, entries 6e11). When
methyl 3-amino-2-thiophenecarboxylate was tested (Table 2, entry
9), the product was not generated as salt. So, we employed a silica
gel column after aqueouswork-up. However, we failed to obtain the
Table 4
Reaction of 6-chloro-2-aminopyrazine with various amidesa
Entry Amide Product Time [min] Yieldb [%]
1c,d 8a 5 85
2c 8b 5 81
3c,e 8c 5 67
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formamidothiophene-2-carboxylate in the column. A similar ten-
dency was also reported when ethyl 2-aminobenzoate was used as
a substrate.8a To avoid the hydrolysis, after extraction, the product
was collected as HCl salt using HCl in diethyl ether. Finally, benzyl
amines were conducted (Table 2, entries 13e15). Since the product
was not precipitated as salt, we had to purify it by column
chromatography.
In addition to aryl and alkyl amines, we have also screened
phenylhydrazide, phenylhydrazine, benzamide, and phenyl-
sulfonamide (Table 3) to demonstrate further use of the method.
Phenylhydrazide and phenylhydrazine gave good results but ben-
zamide gave only N-formylbenzamide in 9% yield. The rest of the
unreacted benzamide was recovered. Phenylsulfonamide was
found to be unsuccessful.Table 3
Expansion of the substratea
Entry Product Time [min] Yieldb [%]
1 7a 10 64
2 7b 5 95
3 7c 10 d
4c 7d 10 16
a Reaction conditions: DMF (1 ml) and phenyl chloroformate (2 equiv) were
stirred for 5 min at rt before addition of the substrates (1 mmol).
b Isolated yield.
c 3 equiv of K2CO3.
4 8d 20 d
5 8e 20 7
6 8f 20 df
7 8g 20 dg
a Reaction conditions: amide (1 ml) and phenyl chloroformate (2 equiv) were
stirred for 10 min at rt before addition of 6-chloro-2-aminopyrazine (1 mmol).
b Isolated yield.
c 45 C.
d 3.5 equiv of phenyl chloroformate.
e 1.5 ml of 4-formylmorpholine.
f No reaction.
g Decomposition.Other N,N-disubstituted amide analogues were tested with 6-
chloro-2-aminopyrazine (Table 4). They were also suitable for for-
mation of the formamidines. But N,N-dimethylacetamide, N-
methylformamide, NMP, and N,N-dimethylbenzamide were found
to be not good for the formation of iminium intermediate with
phenyl chloroformate, giving poor yield or no product.
3. Conclusion
In conclusion, we have discovered that phenyl chloroformate
can be used for the synthesis of the formamidines. Mild conditions,
short reaction time, and generality veriﬁed with various substrates
make this method attractive. Also it is noteworthy that DMF or its
derivatives are not good choice as solvent if chloroformates have to
be used for the synthesis of the carbamate.
4. Experimental
4.1. General
All reactions were carried out under an air atmosphere. All
commercial reagents and solvents were used as received without
further puriﬁcation. The reactions were monitored by TLC using
silica gel plates and column chromatography was performed with
Merck silica gel 60 (230e400 mesh). 1H NMR and 13C NMR spectra
were recorded on Bruker AVANCE III 500. Chemical shift values (d)are given in parts per million using residual solvent as internal
standard. Mass spectra were obtained on an Agilent 6400 Triple
Quadrupole Mass spectrometer instrument using ESI. Melting
points were measured with a Stuart SMP40 apparatus. IR spectra
were recorded on a Smiths IdentifyIR.
4.2. General procedure for the preparation of N,N-dimethyl
formamidines 6, 7
To the DMF (1 ml) was added dropwise phenyl chloroformate
(2 equiv). The mixture was stirred for 5 min at room temperature.
Then 6-chloro-2-aminopyrazine (1 mmol) was introduced to the
mixture. After 5 min, the solvent (isopropyl alcohol:diethyl ether, v/
v¼1:2) was poured into the mixture. The precipitated product 6a
was ﬁltered off, washed with the solvent and dried.
4.2.1. N0-(6-Chloropyrazin-2-yl)-N,N-dimethylformamidine hydro-
chloride (6a). White solid; mp 224e226 C (decomp.); 1H NMR
(500MHz, MeOD) d 9.09 (t, J¼0.7 Hz,1H), 8.64 (d, J¼0.6 Hz,1H), 8.58
(d, J¼0.5 Hz, 1H), 3.57 (d, J¼0.6 Hz, 3H), 3.45 (d, J¼0.8 Hz, 3H); 13C
NMR (126MHz,MeOD) d 154.11,148.22,146.78,142.47,134.28, 45.51,
38.90; LC/MS (ESI) m/z 185 [MþH]þ; IR (ATR): n¼3037, 3012, 2689,
1700,1541,1383,1305,1156, 818 cm1; Anal. Calcd for C7H10Cl2N4: C,
38.03; H, 4.56; N, 25.34. Found: C, 37.6; H, 4.7; N, 25.1. HRMS (ESI)m/
z calcd for C7H10ClN4 [MþH]þ 184.0594, found 184.0596.
4.2.2. N,N-Dimethyl-N0-(pyridin-3-yl)formamidine (6b). To the DMF
was added dropwise phenyl chloroformate. The mixture was stir-
red for 5 min in room temperature. Then 3-aminopyridine was
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with K2CO3(aq), extracted with ethyl acetate and washed with
water. The organic layer was dried over MgSO4, ﬁltered, and con-
centrated. The residue was puriﬁed by column chromatography to
give the product. Colorless oil; 1H NMR (500 MHz, CDCl3)
d 8.30e8.21 (m, 2H), 7.52 (s, 1H), 7.28e7.23 (m, 1H), 7.17 (dd, J¼7.9,
4.8 Hz, 1H), 3.05 (s, 6H). 13C NMR (126MHz, CDCl3) d 153.80, 147.93,
143.68, 143.16, 128.07, 123.52, 40.30, 34.52; LC/MS (ESI) m/z 150
[MþH]þ; IR (ATR): n¼2921, 2808,1628, 1573,1473,1372,1266,1233,
1104, 807, 712 cm1.
4.2.3. N,N-Dimethyl-N0-(pyrazin-2-yl)formamidine (6c). Slightly
yellow oil; 1H NMR (500MHz, CDCl3) d 8.41 (s,1H), 8.26 (d, J¼1.4 Hz,
1H), 8.09 (dd, J¼2.7, 1.5 Hz, 1H), 8.05 (d, J¼2.7 Hz, 1H), 3.09 (d,
J¼1.1 Hz, 6H); 13C NMR (126 MHz, CDCl3) d 158.18, 156.20, 142.14,
141.60, 137.86, 40.97, 34.83; LC/MS (ESI) m/z 151 [MþH]þ; IR (ATR):
n¼3045, 2931, 1614, 1568, 1379, 1099, 1007, 836 cm1.
4.2.4. N0-(5-Bromo-6-chloropyrazin-2-yl)-N,N-dimethylformamidine
hydrochloride (6d). White solid;mp263e266 C (decomp.); 1HNMR
(500MHz,MeOD) d 9.05 (s,1H), 8.44 (s,1H), 3.56 (s, 3H), 3.43 (s, 3H);
13C NMR (126 MHz, MeOD) d 154.21, 148.70, 145.93, 135.81, 134.05,
45.51, 38.89; LC/MS (ESI) m/z 263 [MþH]þ; IR (ATR): n¼2975, 2637,
1692,1417,1297,1163,1024, 832 cm1; Anal. Calcd for C7H9BrCl2N4: C,
28.03; H, 3.02; N, 18.68. Found: C, 28.17; H, 3.01; N, 18.52.
4.2.5. N0-(3,5-Diﬂuorophenyl)-N,N-dimethylformamidine hydrochlo-
ride (6f). White solid; mp 278e281 C; 1H NMR (500 MHz, MeOD)
d 8.74 (s,1H), 7.15 (m, 2H), 6.93 (tt, J¼9.0, 2.2Hz,1H), 3.48 (s, 3H), 3.34
(d, J¼0.6 Hz, 3H); 13C NMR (126MHz,MeOD) d 165.05 (dd, JCF¼247.7,
14.6 Hz), 155.44, 141.22 (t, JCF¼13.1 Hz), 104.00 (m), 102.58 (t,
JCF¼26.0 Hz), 44.74, 38.00; LC/MS (ESI) m/z 185 [MþH]þ; IR (ATR):
n¼3019, 2823, 1695, 1611, 1113, 986 cm1; Anal. Calcd for
C9H11ClF2N2: C, 48.99;H, 5.03;N,12.70. Found: C, 49.3;H, 5.1;N,12.6.
4.2.6. N0-(4-Nitrophenyl)-N,N-dimethyl-formamidine hydrochloride
(6g). White solid; mp 280e282 C; 1H NMR (500 MHz, MeOD)
d 8.87 (s, 1H), 8.34 (d, J¼9.1 Hz, 2H), 7.67 (d, J¼9.1 Hz, 2H), 3.52 (s,
3H), 3.39 (s, 3H); 13C NMR (126 MHz, MeOD) d 154.10, 145.57,
142.69,125.12,119.22, 43.52, 36.76; LC/MS (ESI)m/z 194 [MþH]þ; IR
(ATR): n¼2883,1701, 1597, 1516,1311, 854, 748 cm1; Anal. Calcd for
C9H12ClN3O2: C, 47.07; H, 5.27; N,18.3. Found: C, 47.4; H, 5.1; N,18.0.
4.2.7. N0-(4-Methoxyphenyl)-N,N-dimethylformamidine hydrochlo-
ride (6h). Slightly yellow solid; mp 203e205 C; 1H NMR
(500 MHz, MeOD) d 8.46 (s, 1H), 7.41e7.26 (m, 2H), 7.05e6.90 (m,
2H), 3.81 (s, 3H), 3.41 (s, 3H), 3.27 (d, J¼0.6 Hz, 3H); 13C NMR
(126 MHz, MeOD) d 160.10, 155.30, 131.54, 122.76, 116.00, 56.08,
44.16, 37.42; LC/MS (ESI) m/z 179 [MþH]þ; IR (ATR): n¼2970, 2810,
1689,1507,1341,1236,1019, 794 cm1; Anal. Calcd for C10H15ClN2O:
C, 55.50; H, 7.04; N, 13.05. Found: C, 55.91; H, 7.02; N, 13.04; HRMS
(ESI) m/z calcd for C10H15N2O [MþH]þ 179.1184, found 179.1178.
4.2.8. N0-(2-Hydroxyphenyl)-N,N-dimethylformamidine hydrochlo-
ride (6i). Slightly orange solid; mp 155e157 C; 1H NMR (500 MHz,
MeOD) d 8.42 (s, 1H), 7.28 (dd, J¼7.9, 1.5 Hz, 1H), 7.19 (ddd, J¼8.2,
7.5, 1.6 Hz, 1H), 6.99 (dd, J¼8.2, 1.3 Hz, 1H), 6.91 (td, J¼7.8, 1.3 Hz,
1H), 3.45e3.37 (m, 3H), 3.29 (d, J¼0.6 Hz, 3H); 13C NMR (126 MHz,
MeOD) d 157.09, 151.45, 129.75, 125.69, 124.85, 121.17, 117.54, 44.20,
37.09; LC/MS (ESI) m/z 165 [MþH]þ; IR (ATR): n¼3075, 2966, 1689,
1344, 1281, 1131, 748, 681 cm1; Anal. Calcd for C9H13ClN2O: C,
53.87; H, 6.53; N, 13.96. Found: C, 53.3; H, 6.8; N, 13.9; HRMS (ESI)
m/z calcd for C9H13N2O [MþH]þ 165.1028, found 165.1025.
4.2.9. Methyl N0-(thiophen-3-yl)-N,N-dimethylformamidine-2-
carboxylate hydrochloride (6j). To the DMF was added dropwisephenyl chloroformate. The mixture was stirred for 5 min at room
temperature. Then methyl 3-amino-2-thiophenecarboxylate was
introduced to the mixture. After 5 min, the mixture was basiﬁed
with K2CO3(aq), extracted with ethyl acetate, and washed with
water. The organic layer was dried over MgSO4, ﬁltered, and con-
centrated. The residue was diluted with diethyl ether and HCl (3 M
in diethyl ether) was added. The solution was heated at 35 C for
10 min. The precipitated product 6j was ﬁltered off, washed with
the solvent (isopropyl alcohol:diethyl ether, v/v¼1:2) and dried.
Slightly yellow solid; mp 175e177 C; 1H NMR (500 MHz, MeOD)
d 8.99 (s, 1H), 7.90 (d, J¼5.4 Hz, 1H), 7.49 (d, J¼5.5 Hz, 1H), 3.94 (s,
3H), 3.52 (s, 3H), 3.36 (s, 3H); 13C NMR (126 MHz, MeOD) d 165.03,
155.44, 142.70, 134.78, 120.79, 116.49, 53.20, 44.52, 37.17; LC/MS
(ESI) m/z 213 [MþH]þ; IR (ATR): n¼3452, 3052, 1671, 1584, 1450,
1279, 787 cm1; Anal. Calcd for C9H13ClN2O2S: C, 43.46; H, 5.27; N,
11.26. Found: C, 42.57; H, 5.76; N, 11.27; HRMS (ESI) m/z calcd for
C9H13N2O2S [MþH]þ 213.0698, found 213.0701.
4.2.10. N0-(2-Acetylphenyl)-N,N-dimethylformamidine hydrochloride
(6k). White solid; mp 167e169 C (decomp.); 1H NMR (500 MHz,
MeOD) d 9.11 (s, 1H), 8.23 (d, J¼8.1 Hz, 1H), 7.82e7.73 (m, 2H),
7.51e7.42 (m, 1H), 3.54 (s, 3H), 3.38 (s, 3H), 2.76 (s, 3H); 13C NMR
(126 MHz, MeOD) d 205.26, 154.36, 138.93, 136.63, 134.06, 127.13,
124.59, 118.08, 44.47, 37.37, 28.55; LC/MS (ESI) m/z 191 [MþH]þ; IR
(ATR): n¼3374, 2882, 1683, 1630, 1307, 1255, 774 cm1 Anal. Calcd
for C11H15ClN2O: C, 58.28; H, 6.67; N,12.36. Found: C, 56.3; H, 7.0; N,
11.8; HRMS (ESI) m/z calcd for C11H15N2O [MþH]þ 191.1184, found
191.1183.
4.2.11. N0-(Pyridin-2-yl)-N,N-dimethylformamidine-3-carboxylic acid
hydrochloride (6l). White solid; mp 214e216 C (decomp.); 1H NMR
(500 MHz, MeOD) d 9.47 (s, 1H), 8.61 (dd, J¼4.8, 1.8 Hz, 1H), 8.54
(dd, J¼7.9, 1.8 Hz, 1H), 7.43 (dd, J¼7.9, 4.8 Hz, 1H), 3.58 (s, 3H), 3.41
(d, J¼0.7 Hz, 3H); 13C NMR (126 MHz, MeOD) d 168.72, 152.65,
151.53, 149.37, 141.01, 121.39, 112.16, 43.57, 36.49; LC/MS (ESI) m/z
194 [MþH]þ; IR (ATR): n¼3033, 2280, 1826, 1688, 1638, 1210,
778 cm1; Anal. Calcd for C9H12ClN3O2: C, 47.07; H, 5.27; N, 18.30.
Found: C, 47.04; H, 5.28; N, 18.26.
4.2.12. N0-(Benzo[d]thiazol-2-yl)-N,N-dimethylformamidine hydro-
chloride (6m). White solid; mp 197e200 C; 1H NMR (500 MHz,
MeOD) d 8.57 (s, 1H), 7.87 (d, J¼8.0 Hz, 1H), 7.62e7.52 (m, 2H),
7.48e7.40 (m, 1H), 3.43 (s, 3H), 3.32 (d, J¼3.4 Hz, 3H); 13C NMR
(126 MHz, MeOD) d 176.00, 162.64, 138.89, 129.44, 126.86, 126.61,
124.24,115.84, 42.69, 36.93; LC/MS (ESI)m/z 206 [MþH]þ; IR (ATR):
n¼2425, 1637, 1535, 1458, 1394, 1186, 773 cm1; Anal. Calcd for
C10H12ClN3S: C, 49.69; H, 5.00; N, 17.38. Found: C, 49.11; H, 5.01; N,
17.32; HRMS (ESI)m/z calcd for C10H12N3S[MþH]þ 206.0752, found
206.0755.
4.2.13. N0-Benzyl-N,N-dimethylformamidine (6n). Slightly yellow
oil; 1H NMR (500 MHz, MeOD) d 7.52 (s, 1H), 7.29 (m, 2H), 7.24 (m,
2H), 7.21 (m, 1H), 4.39 (s, 2H), 2.90 (s, 6H); 13C NMR (126 MHz,
MeOD) d 158.75, 142.90, 129.29, 128.55, 127.64, 59.47, 38.18; LC/MS
(ESI) m/z 163 [MþH]þ; IR (ATR): n¼3031, 1658, 1383, 1238,
696 cm1.
4.2 .14 . N 0-(4-Methoxybenzyl)-N,N-dimethyl formamidine
(6o). Slightly yellow oil; 1H NMR (500 MHz, CDCl3) d 7.36 (s, 1H),
7.19 (d, J¼8.4 Hz, 2H), 6.84 (d, J¼8.6 Hz, 2H), 4.39 (s, 2H), 3.77 (s,
3H), 2.89 (s, 6H); 13C NMR (126 MHz, CDCl3) d 158.43, 155.69,
133.96, 128.76, 113.82, 58.19, 55.37, 37.54; LC/MS (ESI) m/z 193
[MþH]þ; IR (ATR): n¼2933, 2836, 1646, 1510, 1242, 1059, 816 cm1.
4.2.15. N0-(4-(Triﬂuoromethyl)benzyl)-N,N-dimethylformamidine
(6p). Slightly yellow oil; 1H NMR (500 MHz, CDCl3) d 7.55 (d,
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NMR (126 MHz, CDCl3) d 156.17, 146.57, 128.55 (q, J¼32.2 Hz),
127.67, 125.11 (q, JCF¼3.8 Hz), 124.43 (q, JCF¼271.7 Hz), 59.08, 37.77;
LC/MS (ESI) m/z 231 [MþH]þ; IR (ATR): n¼2871, 1648, 1321, 1108,
1065, 1017, 819 cm1.
4.2.16. N0-Benzoyl-N,N-dimethylformohydrazonamide (7a). The
procedure is samewith 6c. Slightly yellow solid; mp 171e173 C; 1H
NMR (500MHz, CDCl3) d 8.79 (s,1H), 7.90 (s,1H), 7.79e7.73 (m, 2H),
7.46e7.41 (m, 1H), 7.40e7.33 (m, 2H), 2.86 (s, 6H); 13C NMR
(126 MHz, CDCl3) d 180.30, 164.84, 157.95, 134.53, 131.12, 128.60,
126.97, 37.92; LC/MS (ESI)m/z 192 [MþH]þ; IR (ATR): n¼3216, 3064,
2905, 1603, 1572, 1355, 1110, 902, 694 cm1.
4.2.17. N,N-Dimethyl-N0-phenylformohydrazonamide hydrochloride
(7b). Slightly yellow solid; mp 201e203 C; 1H NMR (500 MHz,
MeOD) d 8.32 (s, 1H), 7.28 (t, J¼7.1 Hz, 2H), 7.03e6.86 (m, 3H), 3.35
(s, 3H), 3.19 (s, 3H); 13C NMR (126 MHz, MeOD) d 159.82, 147.06,
128.96, 121.53, 113.44, 42.60, 36.27; LC/MS (ESI) m/z 164 [MþH]þ;
IR (ATR): n¼3190, 2977, 2770, 1707, 1486, 770, 753, 703 cm1; Anal.
Calcd for C9H14ClN3: C, 54.14; H, 7.07; N, 21.04. Found: C, 54.1; H,
7.2; N, 21.10.
4.2.18. N,N-Dimethyl-N0-(phenylsulfonyl)formamidine (7d). White
solid; mp 128e130 C; 1H NMR (500 MHz, CDCl3) d 8.13 (s, 1H),
7.91e7.84 (m, 2H), 7.54e7.47 (m,1H), 7.47e7.42 (m, 2H), 3.12 (s, 3H),
3.01 (s, 3H); 13C NMR (126 MHz, CDCl3) d 159.33, 142.52, 131.94,
128.81, 126.56, 41.61, 35.64; LC/MS (ESI)m/z 213 [MþH]þ; IR (ATR):
n¼2930, 1613, 1280, 1145, 1086, 906, 846, 685 cm1.
4.3. General procedure for reaction of 6-chloro-2-
aminopyrazine with amides
To theN,N-diethylformamide (1ml) was added dropwise phenyl
chloroformate (3.5 equiv). The mixture was stirred for 10 min at
room temperature. Then 6-chloro-2-aminopyrazine (1 mmol) was
introduced to the mixture. After 5 min at 45 C, the mixture was
basiﬁed with K2CO3(aq), extracted with ethyl acetate and washed
with water. The organic layer was dried over MgSO4, ﬁltered, and
concentrated. The residue was puriﬁed by column chromatography
to give the product.
4.3.1. N 0-(6-Chloropyrazin-2-yl)-N,N-diethylformamidine
(8a). Slightly yellow oil; 1H NMR (500 MHz, CDCl3) d 8.48 (s, 1H),
8.12 (s,1H), 8.04 (s, 1H), 3.59 (q, J¼7.2 Hz, 2H), 3.40 (q, J¼7.2 Hz, 2H),
1.25 (t, J¼7.2 Hz, 3H), 1.21 (t, J¼7.2 Hz, 3H); 13C NMR (126 MHz,
CDCl3) d 158.04, 155.89, 146.72, 139.11, 135.72, 46.52, 40.09, 14.93,
12.48; LC/MS (ESI) m/z 213 [MþH]þ; IR (ATR): n¼2975, 2936, 2875,
1605, 1387, 1158, 1115 cm1.
4.3.2. 6-Chloro-N-(piperidin-1-ylmethylene)pyrazin-2-amine
(8b). Slightly yellow solid; mp 71e73 C; 1H NMR (500MHz, CDCl3)
d 8.49 (s, 1H), 8.12 (s, 1H), 8.04 (s, 1H), 3.73 (m, 2H), 3.44 (m, 2H),
1.67 (m, 6H); 13C NMR (126 MHz, CDCl3) d 158.03, 155.48, 146.74,
138.98,135.76, 51.54, 44.02, 26.69, 25.21, 24.51; LC/MS (ESI)m/z 225
[MþH]þ; IR (ATR): n¼3069, 2941, 2855,1696, 1607, 1353,1157,1000,
858 cm1.
4.3.3. 6-Chloro-N-(morpholinomethylene)pyrazin-2-amine
(8c). Slightly yellow solid; mp 121e123 C; 1H NMR (500 MHz,CDCl3) d 8.52 (s, 1H), 8.13 (s, 1H), 8.10 (s, 1H), 3.82 (m, 2H), 3.75 (m,
4H), 3.51 (m, 2H); 13C NMR (126 MHz, CDCl3) d 157.33, 155.43,
146.79, 139.01, 136.64, 67.15, 66.35, 50.04, 43.70; LC/MS (ESI) m/z
227 [MþH]þ; IR (ATR): n¼2980, 2911, 2867, 1609, 1389, 1348, 1162,
1104, 1006, 848 cm1.
4.3.4. 6-Chloro-N-(1-methylpyrrolidin-2-ylidene)pyrazin-2-amine
(8e). Slightly yellow oil; 1H NMR (500 MHz, CDCl3) d 8.11 (s, 1H),
8.00 (s, 1H), 3.45 (t, J¼7.1 Hz, 2H), 3.06 (s, 3H), 2.94 (t, J¼7.9 Hz, 2H),
2.06 (dt, J¼15.2, 7.6 Hz, 2H); 13C NMR (126 MHz, CDCl3) d 167.47,
158.76, 146.37,139.50, 134.69, 51.38, 31.80, 29.69, 19.88; LC/MS (ESI)
m/z 211 [MþH]þ; IR (ATR): n¼2925, 2870, 2175, 1590, 1469, 1379,
1288, 1158, 1001, 921 cm1.
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